All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – Shanghai-headquartered Inventisbio Inc. brought in $147 million from a series D funding round to move its main products into phase II trials in the U.S. and China.
